Transaminase Test Market Report: Market Size & Forecast 2026

Transaminase tests, measuring enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), are fundamental tools in diagnosing and monitoring hepatocellular injury and are a core component of liver function test (LFT) panels. The global market was estimated at USD 4.10 billion in 2024, rising to approximately USD 4.5 billion in 2025, and is projected to reach USD 7.81 billion by 2033 at a CAGR of 7.0%. The overall liver function tests market is also expected to reach USD 52.4 billion by 2030, reflecting the outsized role that transaminase testing plays within the broader diagnostic landscape. Demand is underpinned by the integration of LFT panels into standard blood workups, with transaminases being among the most frequently ordered clinical chemistry assays globally.

• •Market valued at ~USD 4.5 billion in 2025, growing at 7.0% CAGR toward ~USD 7.81 billion by 2033
• •Encompasses ALT, AST, and related enzyme assays critical for detecting liver cell damage
• •Forms a key segment within the USD 39.5 billion liver disease diagnostics market and USD 97+ billion global blood testing industry

The global burden of liver diseases is a primary catalyst, with non-alcoholic fatty liver disease alone affecting an estimated 1 in 4 adults worldwide, while viral hepatitis continues to impact hundreds of millions globally. Rising prevalence of diabetes and obesity, two leading risk factors for NAFLD, alongside aging demographics in North America, Europe, and Asia-Pacific are steadily increasing the pool of patients requiring liver enzyme monitoring. Greater healthcare spending, expanding access to clinical laboratory services in developing regions, and the growing preference for early disease detection through preventive screening programs are further reinforcing demand. Technological advancements in high-throughput immunoassay platforms and point-of-care transaminase testing are also lowering barriers to broader utilization.

• •Rising global prevalence of NAFLD, viral hepatitis, and alcohol-related liver disease drives sustained clinical demand
• •Aging population and increasing rates of diabetes and obesity expand the pool of patients requiring routine liver monitoring
• •Expanding healthcare infrastructure, preventive screening programs, and improved diagnostic technology adoption accelerate market growth

North America currently holds the largest share of the transaminase test market, supported by advanced healthcare infrastructure, high diagnostic test volumes, and strong awareness of liver disease screening. Europe follows closely, while the Asia-Pacific region is expected to register the fastest growth due to rising healthcare access, increasing disease burden, and growing investments in diagnostic capabilities across China, India, and Southeast Asian economies. The market is segmented by test type, primarily ALT, AST, and combination LFT panels, across hospital laboratories, standalone diagnostic laboratories, and point-of-care settings. The broader hepatic markers market, closely related to transaminase testing, is projected to grow from USD 2.6 billion in 2025 to USD 4.6 billion by 2035 at a CAGR of 5.9%.

• •North America leads in market share; Asia-Pacific is the fastest-growing region driven by rising healthcare investment and disease burden
• •Segments include standalone ALT/AST tests and bundled liver function panels across hospital labs, reference labs, and point-of-care settings
• •Hepatic markers sub-market grows from USD 2.6 billion (2025) to USD 4.6 billion by 2035, complementing broader transaminase test expansion

What are the recent trends and outlook?

Emerging trends are reshaping the transaminase testing landscape, including the development of rapid point-of-care ALT/AST devices suitable for decentralized settings such as primary care clinics and community health centers. The integration of artificial intelligence and digital platforms with laboratory diagnostics is enabling smarter result interpretation, patient risk stratification, and connectivity with electronic health records. There is growing emphasis on early NAFLD screening protocols in primary care, which is expanding the routine use of transaminase tests beyond traditional hepatology and gastroenterology settings. Over the medium to long term, the market is expected to benefit from biomarker-driven personalized medicine approaches, multiplex liver panels combining transaminases with fibrosis markers, and continued expansion of diagnostic services in underserved emerging markets.

• •Point-of-care transaminase testing and AI-integrated diagnostic platforms are emerging as key innovation frontiers
• •Expanding use of transaminase tests in primary care for NAFLD and metabolic syndrome screening broadens market reach
• •Multiplex liver panels and fibrosis biomarker integration are expected to drive next-generation product development and market differentiation